AbbVie (ABBV) Interest & Investment Income (2012 - 2026)

AbbVie has disclosed Interest & Investment Income across 15 years of filings, most recently posting -$645.0 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 2.87% year-over-year to -$645.0 million; the TTM figure through Mar 2026 stood at -$2.6 billion (down 13.32% YoY), while the FY2025 annual figure was -$2.6 billion, down 21.62% from the prior year.
• Interest & Investment Income improved to -$645.0 million in Q1 2026, from -$655.0 million in the prior quarter.
• Over the last five years, Interest & Investment Income for ABBV reached as high as -$378.0 million in Q4 2023 and fell as low as -$678.0 million in Q2 2025.
• The 5-year median for Interest & Investment Income is -$532.0 million (2022), against an average of -$538.8 million.
• Annual changes were most pronounced in 2023 — Interest & Investment Income gained 20.59% — and 2024, when it plunged 61.38%.
• A 5-year view of Interest & Investment Income shows it stood at -$476.0 million in 2022, then grew by 20.59% to -$378.0 million in 2023, then sank by 61.38% to -$610.0 million in 2024, then declined by 7.38% to -$655.0 million in 2025, then rose by 1.53% to -$645.0 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$645.0 million, -$655.0 million, and -$667.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.